Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × Nalbuphine Allergy × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 1616 Neoplasms 1105 Colorectal Neoplasms 927 Carcinoma, Non-Small-Cell Lung 900 Carcinoma, Hepatocellular 712 Stomach Neoplasms 708 Lung Neoplasms 677 Prostatic Neoplasms 615 Pancreatic Neoplasms 501 Rectal Neoplasms 389 Neoplasm Metastasis 364 Ovarian Neoplasms 359 Colonic Neoplasms 357 Recurrence 349 Uterine Cervical Neoplasms 342 Leukemia, Myeloid, Acute 333 Esophageal Neoplasms 307 Multiple Myeloma 304 Head and Neck Neoplasms 291 Lymphoma 288 Melanoma 281 Precursor Cell Lymphoblastic Leukemia-Lymphoma 248 Brain Neoplasms 244 Urinary Bladder Neoplasms 227 Nasopharyngeal Carcinoma 204 Leukemia 197 Lymphoma, Large B-Cell, Diffuse 196 Liver Neoplasms 195 Polycystic Ovary Syndrome 184 Squamous Cell Carcinoma of Head and Neck 179

Interventions

Nalbuphine 1 Morphine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05073744 2022-12-29

Nalbuphine Versus Morphine for Perioperative Tumor Ablation

Zhongda Hospital

Phase 4 Unknown

Nalbuphine Allergy

Data powered by HemOnc (CC BY 4.0) Colophon ⚡